NXEN
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $0 | -$13,021 |
| 2024 Q2 | -0.00 | $0 | -$28,647 |
| 2024 Q1 | -0.00 | $0 | -$9,230 |
| 2024 Q4 | -0.00 | $0 | -$10,880 |
| 2024 Q3 | -0.00 | $0 | -$20,952 |
| 2023 Q2 | -0.00 | $0 | -$15,445 |
| 2023 Q1 | -0.00 | $0 | -$17,083 |
| 2023 Q4 | -0.00 | $0 | -$19,060 |